List of Excipients in Branded Drug DEHYDRATED ALCOHOL

Dehydrated Alcohol Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Dehydrated alcohol, also called anhydrous ethanol or absolute alcohol, is a high-purity ethanol excipient used primarily as a solvent, cosolvent, preservative-supporting vehicle, extraction medium, and delivery-system component. Its commercial value is concentrated in regulated quality, low-impurity supply, formulation performance, and documentation rather than in standalone patent exclusivity.

The strongest opportunities are pharmaceutical-grade ethanol for oral liquids, topical products, inhalation formulations, botanical and active-ingredient extraction, specialty compounding, and low-water or water-sensitive drug products. The principal constraints are flammability, pediatric ethanol exposure, residual impurities, alcohol labeling, excise-tax treatment, and the availability of lower-risk substitutes such as propylene glycol, glycerin, polyethylene glycol, and hydroalcoholic systems with reduced ethanol content.

What is dehydrated alcohol in pharmaceutical manufacturing?

Dehydrated alcohol is ethanol containing a very low level of water. USP-NF defines Alcohol, Dehydrated as ethanol containing not less than 99.5% by volume of ethanol at 15.56°C, subject to applicable compendial requirements.[1]

Commercial grades differ materially in regulatory suitability:

Grade	Typical use	Key issue
USP-NF dehydrated alcohol	Drug products, compounding, extraction	Requires compendial quality and qualified supply
Ph. Eur. anhydrous ethanol	European pharmaceutical manufacturing	Must meet European Pharmacopoeia specifications
Undenatured ethanol	Oral and parenteral pharmaceutical products	Excise-tax and diversion controls may apply
Denatured ethanol	Topical products, manufacturing, laboratory use	Denaturants can create toxicity and regulatory barriers
Technical or industrial ethanol	Industrial processing	Usually unsuitable for drug products
Bio-based ethanol	Pharmaceutical and consumer products	Requires control of feedstock, impurities, and supply consistency

Dehydrated alcohol is an excipient when it performs a formulation function. It is an active ingredient when the product is intended to produce a pharmacologic or therapeutic effect from ethanol itself, such as certain injectable alcohol products. The distinction affects labeling, regulatory classification, patent analysis, and product development.

What pharmaceutical functions does dehydrated alcohol provide?

Dehydrated alcohol is used because it combines solvent power, volatility, water miscibility, antimicrobial activity, and compatibility with a broad range of organic compounds.

Solvent and cosolvent

Ethanol improves the solubility of active pharmaceutical ingredients that have limited water solubility. It is used in oral solutions, elixirs, sprays, drops, topical liquids, and some parenteral formulations.

The formulation benefit depends on concentration. A higher ethanol content can increase drug solubility but can also increase irritation, flammability, taste burden, evaporative loss, and pediatric exposure.

Extraction medium

Pharmaceutical and nutraceutical manufacturers use ethanol-water mixtures to extract botanical constituents, flavors, fragrances, and other natural products. Dehydrated alcohol is valuable when a low-water extraction step is required or when the final process requires controlled solvent composition.

Preservation support

Ethanol can contribute antimicrobial activity, but it should not be treated as a universal preservative. Preservative performance depends on concentration, formulation pH, packaging, microbial challenge results, and the presence of other excipients.

Volatility and rapid drying

Topical antiseptic products, transdermal systems, sprays, and certain medical-device products use ethanol for fast evaporation. The same property creates manufacturing and packaging requirements for closed transfer, vapor control, and container-closure integrity.

Solubilization in delivery systems

Ethanol is used in some metered-dose inhalation and nasal systems, although its role depends on device design, aerosol performance, patient tolerability, and residual solvent controls. It can also support permeation in topical and transdermal products.

What regulatory requirements apply to dehydrated alcohol excipients?

FDA expects excipients to be suitable for their intended use and controlled under applicable current good manufacturing practice requirements. Drug manufacturers must establish identity, strength, quality, purity, and safety through supplier qualification, incoming testing, process controls, and finished-product testing.[2]

Compendial controls

A pharmaceutical supplier should control at least:

• Ethanol assay
• Water content
• Specific gravity or density
• Acidity or alkalinity
• Residue on evaporation
• Organic impurities
• Methanol
• Acetaldehyde and other aldehydes
• Benzene and other volatile contaminants
• Denaturants, where applicable
• Elemental impurities
• Microbial quality where relevant

Methanol is a high-priority contaminant because it can cause severe toxicity and blindness. Benzene is a major quality concern because it is a recognized human carcinogen and is not an acceptable intentional component of pharmaceutical ethanol. FDA has issued communications on contaminated alcohol-based products and expects manufacturers to test high-risk components where warranted.[3]

Alcohol content and labeling

Products containing ethanol require an assessment of labeling obligations, patient exposure, and jurisdiction-specific alcohol controls. The risk is highest in oral liquids, pediatric medicines, pregnancy-related products, chronic-use products, and products used by patients with alcohol-use disorders.

The European Medicines Agency has issued guidance on ethanol as an excipient, including requirements for disclosure and warnings based on the amount of ethanol per dose and patient population.[4] U.S. requirements depend on product category and labeling framework, but sponsors generally need a documented exposure assessment and a defensible benefit-risk rationale.

FDA inactive ingredient status

Dehydrated alcohol and ethanol have historical use in FDA-regulated drug products. The FDA Inactive Ingredient Database can support precedent analysis, but database presence does not establish approval for every route, concentration, dosage form, or patient population.[5]

An excipient supplier should evaluate:

1. Route of administration.
2. Maximum concentration.
3. Maximum daily exposure.
4. Age group and vulnerable populations.
5. Product type and dosage form.
6. Prior FDA use in comparable products.
7. Local tolerability and systemic ethanol exposure.

What formulations are protected by dehydrated alcohol?

Dehydrated alcohol itself generally has limited standalone patent protection because ethanol is an established commodity excipient. Commercial protection usually arises from the finished formulation, delivery system, manufacturing process, or specific use.

Protection category	Typical claim subject matter	Commercial relevance
Formulation patent	Ethanol concentration with active ingredient and co-solvents	Can delay substitution or support differentiated products
Low-water formulation	Stable drug product using anhydrous ethanol	Useful for hydrolysis-sensitive molecules
Extraction process	Ethanol-based extraction and purification	Relevant to botanical and specialty APIs
Delivery system	Ethanol-containing spray, aerosol, gel, or transdermal system	May protect device-formulation interaction
Manufacturing process	Closed handling, recovery, or impurity-control process	Usually protects operations rather than market access
Packaging patent	Vapor-control container or closure	Can improve shelf life and transport safety
Use patent	Ethanol-containing formulation for a specific indication	May create method-of-use exposure

The most defensible intellectual-property strategy is to claim a technical result, such as improved stability, reduced precipitation, controlled evaporation, enhanced delivery, or a defined impurity profile. A claim directed only to using dehydrated alcohol as a solvent is likely to face prior-art pressure.

How strong is the patent estate for dehydrated alcohol?

The patent estate for the excipient itself is weak. Dehydrated alcohol is an established chemical with extensive prior art, broad commercial availability, and multiple pharmacopeial specifications.

Patent strength is higher in these areas:

• Novel ethanol-water ratios that produce an unexpected stability or delivery result.
• Ethanol-containing formulations for difficult-to-solubilize APIs.
• Controlled-release or transdermal systems using ethanol as a permeation enhancer.
• Low-temperature or closed-loop recovery processes that reduce impurities.
• Formulations that maintain ethanol concentration over shelf life.
• Packaging systems that limit ethanol evaporation and preserve dose uniformity.
• Specialized extraction processes with improved selectivity or yield.

A patent review should focus on the finished drug, formulation owner, and delivery technology. There is generally no meaningful Orange Book exclusivity associated with dehydrated alcohol as an excipient.

What is the Orange Book status of dehydrated alcohol?

Dehydrated alcohol is not an Orange Book-listed drug product merely because it is used as an inactive ingredient. The FDA Orange Book lists approved drug products and related patent and exclusivity information, not commodity excipients as independent sources of formulation exclusivity.[6]

Where ethanol is the active ingredient in an approved drug product, the relevant product may be listed under its drug product name and active ingredient. That status should not be confused with patent protection for pharmaceutical-grade ethanol sold as an excipient.

When does dehydrated alcohol lose exclusivity?

Dehydrated alcohol has no conventional branded-drug exclusivity period when sold as a compendial excipient. Market protection depends on qualification status, manufacturing capacity, regulatory documentation, customer switching costs, and supply reliability.

For an ethanol-containing finished drug:

• New chemical entity exclusivity may apply to the active drug, not to ethanol.
• New formulation exclusivity may apply to the finished product in limited circumstances.
• Method-of-use patents may cover a clinical use.
• Formulation patents may restrict competing products.
• Orphan-drug exclusivity may apply to the approved indication.
• Pediatric exclusivity can extend certain listed protections.

FDA patent-term restoration and regulatory exclusivity are product-specific. They do not create a separate exclusivity term for dehydrated alcohol as an excipient.[6][7]

What commercial opportunities exist for pharmaceutical-grade dehydrated alcohol?

Premium impurity-controlled supply

The clearest opportunity is a validated, documentation-heavy supply platform offering:

• USP-NF and Ph. Eur. compliance.
• Lot-level certificates of analysis.
• Low benzene and low methanol controls.
• Dedicated pharmaceutical storage and transfer.
• Full traceability to feedstock and production site.
• Audit support and change-control notification.
• Stability and packaging data.
• Global regulatory support.

Customers may pay a premium for reliability even when ethanol itself is inexpensive. The value increases when the product is used in a registered medicine where supplier changes require regulatory assessment.

Sustainable and low-carbon ethanol

Bio-based ethanol can support environmental targets for pharmaceutical manufacturers. The commercial proposition is strongest when the supplier can document feedstock origin, mass balance, carbon intensity, chain of custody, and consistent impurity performance.

Sustainability claims do not replace pharmacopeial compliance. A lower-carbon product that lacks robust impurity data will not displace a qualified pharmaceutical supplier.

Specialty denatured systems

Topical and industrial pharmaceutical applications may use denatured ethanol to reduce diversion and tax exposure. The denaturant must be compatible with the intended route, product labeling, toxicology profile, and manufacturing process.

A supplier can differentiate through prequalified denaturing systems, regulatory mapping by jurisdiction, and formulations designed to avoid objectionable odor, residue, or skin irritation.

Small-volume and regional supply

Hospitals, compounding pharmacies, clinical-trial manufacturers, and specialty formulators may need smaller quantities than large oral-liquid or topical manufacturers. Packaging in validated drums, totes, and smaller containers can create margin opportunities, provided flammable-liquid transport and storage requirements are controlled.

Contract formulation and extraction

Ethanol expertise can support contract development for:

• Botanical extracts.
• Cannabinoid and terpene products.
• Oral solutions and sprays.
• Topical antiseptics.
• Transdermal products.
• Drug-device combinations.
• Low-water formulations.
• Solvent-recovery processes.

The higher-value service is process and regulatory integration, not ethanol resale alone.

Which companies are challenging pharmaceutical-grade ethanol suppliers?

Competition is fragmented across global alcohol producers, specialty chemical companies, excipient distributors, and regional pharmaceutical suppliers. Large producers often compete on scale and feedstock economics. Specialty suppliers compete on qualification packages, packaging, regional availability, and customer service.

A buyer should assess:

Competitive factor	Why it matters
Production source	Determines impurity profile and supply risk
Dedicated pharmaceutical line	Reduces contamination and change-control risk
Geographic redundancy	Limits interruption exposure
Denatured and undenatured capability	Supports multiple product categories
Regulatory documentation	Reduces customer qualification time
Recovery and recycling systems	Lowers cost and environmental burden
Flammable-goods logistics	Affects delivered cost and lead time
Change-control discipline	Protects registered product continuity

Supplier concentration can create more commercial leverage than patent rights. A validated second source may have substantial value to a drug manufacturer facing continuity risk.

What generic entry risks exist for ethanol-containing drug products?

Generic entry risk depends on the active ingredient, dosage form, route, and formulation complexity. Ethanol alone is rarely a barrier to generic entry.

Risk is higher when:

• Ethanol is critical to API solubility.
• The formulation has a narrow concentration window.
• Ethanol evaporation changes dose uniformity.
• The product uses a specialized spray or aerosol device.
• The formulation depends on a protected excipient combination.
• Stability is sensitive to water ingress.
• Taste masking or pediatric tolerability requires a specific composition.
• The reference product has difficult-to-reproduce extraction or manufacturing steps.

A generic sponsor may replace ethanol with propylene glycol, glycerin, polyethylene glycol, or another cosolvent. Such substitution can alter solubility, viscosity, taste, spray pattern, absorption, preservative performance, and stability. These differences can create development work but do not necessarily prevent approval.

What litigation and Paragraph IV issues affect dehydrated alcohol?

There is no standard Paragraph IV pathway directed to dehydrated alcohol as an excipient. Paragraph IV litigation generally concerns patents listed for an approved drug product, including formulation, method-of-use, or drug-device patents.[8]

An ethanol-containing product can face patent litigation when:

• The reference product has an Orange Book-listed formulation patent.
• The product uses a patented delivery device.
• A method-of-use patent covers the indication.
• A process patent is asserted outside the Orange Book framework.
• A generic substitutes or reproduces a protected solvent system.

Settlement agreements may include delayed launch dates, licenses, authorized-generic arrangements, or restrictions tied to formulation and indication claims. The presence of ethanol does not, by itself, indicate litigation risk.

How does dehydrated alcohol compare with alternative pharmaceutical excipients?

Excipient	Main advantage	Main limitation
Dehydrated alcohol	Strong solvent power, volatility, rapid drying	Flammability, taste, exposure, evaporation
Propylene glycol	Broad solvent use and lower volatility	Toxicity concerns at high exposure; pediatric limitations
Glycerin	Good solubilization and humectancy	Viscosity, sweetness, gastrointestinal effects
PEG 400	Useful for poorly soluble APIs	Oxidation and impurity considerations
Polysorbates	Solubilization and emulsification	Peroxide formation and degradation risk
Transcutol-type solvents	Topical and transdermal delivery	Route-specific safety and regulatory review
Water	Low cost and patient acceptability	Poor solvent for many hydrophobic APIs; hydrolysis risk

The optimal strategy is often a mixed-solvent system. Reducing ethanol while preserving solubility can improve tolerability and lower regulatory exposure, but it may create precipitation or stability problems.

What geographic markets offer the strongest opportunities?

North America and Europe offer premium opportunities for documented pharmaceutical-grade material, although requirements are demanding. Europe places particular emphasis on ethanol exposure labeling and excipient information. Emerging markets may offer volume growth in oral liquids, topical antiseptics, herbal extracts, and generic formulations, but local rules on denaturing, alcohol taxation, importation, and pharmacopoeial equivalence must be assessed.

Global suppliers should maintain region-specific documentation for:

• USP-NF compliance.
• Ph. Eur. compliance.
• National pharmacopoeial acceptance.
• Alcohol licensing.
• Excise-tax treatment.
• Dangerous-goods transport.
• Import permits.
• Denaturant rules.
• Local labeling requirements.

Key Takeaways

• Dehydrated alcohol is a high-utility pharmaceutical excipient, but its standalone patent protection is limited.
• Commercial differentiation depends on purity, low methanol and benzene levels, supply continuity, documentation, and validated handling.
• The best opportunities are premium pharmaceutical supply, sustainable ethanol, specialty denatured systems, contract extraction, and low-water formulation development.
• Orange Book and Paragraph IV exposure generally attach to the finished ethanol-containing drug, not to ethanol as an excipient.
• Formulation patents are strongest when they claim a measurable technical benefit rather than ethanol use alone.
• Pediatric oral liquids, chronic-use medicines, and inhaled or topical products require close assessment of ethanol exposure and labeling.
• Supplier qualification, flammable-liquid logistics, impurity control, and geographic redundancy can create greater commercial value than excipient patent rights.

FAQs About Dehydrated Alcohol in Pharmaceutical Formulations

Is dehydrated alcohol the same as absolute ethanol?

They are closely related terms. Dehydrated alcohol is pharmaceutical-grade ethanol controlled to a very low water content. “Absolute ethanol” is commonly used as a technical description, but the applicable pharmacopoeial specification controls regulatory acceptability.

Can dehydrated alcohol be used in pediatric medicines?

It can be used in some pediatric formulations, but exposure must be assessed by dose, age, frequency, and product type. Ethanol content may create labeling, safety, and formulation challenges, especially for chronic-use medicines.

Is dehydrated alcohol an FDA-approved excipient?

FDA evaluates excipient use in the context of a specific drug product. Historical presence in the FDA Inactive Ingredient Database can support precedent but does not automatically establish suitability for every route or concentration.[5]

Can a pharmaceutical company patent an ethanol-containing formulation?

Yes. Protection may be available for a novel composition, concentration range, delivery system, stability profile, manufacturing process, or therapeutic use. The claim must provide a patentable technical distinction over existing ethanol formulations.

Does pharmaceutical-grade ethanol require a second source?

A second source is not universally mandatory, but it can reduce supply interruption and regulatory continuity risk. The alternate supplier must undergo qualification, comparability review, and change-control assessment before use in a registered product.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Alcohol, Dehydrated monograph. USP Convention.

2. U.S. Food and Drug Administration. (2023). Current good manufacturing practice, quality systems approach, and pharmaceutical quality resources. FDA.

3. U.S. Food and Drug Administration. (2023). FDA updates on hand sanitizers and alcohol-based products contaminated with methanol or 1-propanol. FDA.

4. European Medicines Agency. (2018). Information for the package leaflet regarding ethanol used as an excipient in medicinal products for human use. EMA.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

7. U.S. Food and Drug Administration. (2024). Small business and industry assistance: Exclusivity and patent provisions. FDA.

8. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format, including patent certifications under 21 CFR 314.101 and 314.107. FDA.